<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>386-OLAPARIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OLAPARIB" rxcui="1597582">
<ATC code="L01XX46" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of olaparib by the amiodarone</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, limit the dose of olaparib to 200 mg twice a day with the amiodarone</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>386-OLAPARIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OLAPARIB" rxcui="1597582">
<ATC code="L01XX46" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of olaparib by the diltiazam</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, limit the dose of olaparib to 200 mg twice a day. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>386-OLAPARIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OLAPARIB" rxcui="1597582">
<ATC code="L01XX46" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of olaparib by the fluconazole</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, limit the dose of olaparib to 200 mg twice a day.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>386-OLAPARIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OLAPARIB" rxcui="1597582">
<ATC code="L01XX46" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYME INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease, possibly very large depending on the inducer, of the plasma concentrations of the olaparib due to increase of its hepatique metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>386-OLAPARIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OLAPARIB" rxcui="1597582">
<ATC code="L01XX46" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of olaparib by the inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, limit the dose of olaparib to 150 mg twice a day.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>386-OLAPARIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OLAPARIB" rxcui="1597582">
<ATC code="L01XX46" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of olaparib by the verapamil.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, limit the dose of olaparid to 200 mg twice a day.</COMMENT>
</INTERACTION>
</INTERACTIONS>
